Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/37442
Title: The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019)
Authors: Gardenbroek, T. J.
Pinkney, T. D.
Sahami, S.
Morton, D. G.
Buskens, C. J.
Ponsioen, C. Y.
Tanis, P. J.
Löwenberg, M.
van den Brink, G. R.
Broeders, I. A. M. J.
Pullens, P. H. J. M.
Seerden, T.
Boom, M. J.
Mallant-Hent, R. C.
Pierik, R. E. G. J. M.
Vecht, J.
Sosef, M. N.
van Nunen, A. B.
van Wagensveld, B. A.
Stokkers, P. C. F.
Gerhards, M. F.
Jansen, J. M.
Acherman, Y.
Depla, A. C. T. M.
Mannaerts, G. H. H.
West, R.
Iqbal, T.
Pathmakanthan, S.
Howard, R.
Magill, L.
Singh, Baljit
Oo, Y. H.
Negpodiev, D.
Dijkgraaf, M. G. W.
D’Haens, G. R. A. M.
Bemelman, W. A
First Published: 18-Mar-2015
Publisher: BioMed Central
Citation: BMC Surgery 2015 15:30
Abstract: Background Over the past 20 years evidence has accumulated confirming the immunomodulatory role of the appendix in ulcerative colitis (UC). This led to the idea that appendectomy might alter the clinical course of established UC. The objective of this body of research is to evaluate the short-term and medium-term efficacy of appendectomy to maintain remission in patients with UC, and to establish the acceptability and cost-effectiveness of the intervention compared to standard treatment. Methods/Design These paired phase III multicenter prospective randomised studies will include patients over 18 years of age with an established diagnosis of ulcerative colitis and a disease relapse within 12 months prior to randomisation. Patients need to have been medically treated until complete clinical (Mayo score <3) and endoscopic (Mayo score 0 or 1) remission. Patients will then be randomised 1:1 to a control group (maintenance 5-ASA treatment, no appendectomy) or elective laparoscopic appendectomy plus maintenance treatment. The primary outcome measure is the one year cumulative UC relapse rate - defined both clinically and endoscopically as a total Mayo-score ≥5 with endoscopic subscore of 2 or 3. Secondary outcomes that will be assessed include the number of relapses per patient at 12 months, the time to first relapse, health related quality of life and treatment costs, and number of colectomies in each arm. Discussion The ACCURE and ACCURE-UK trials will provide evidence on the role and acceptability of appendectomy in the treatment of ulcerative colitis and the effects of appendectomy on the disease course. Trial registration NTR2883; ISRCTN56523019
DOI Link: 10.1186/s12893-015-0017-1
ISSN: 1471-2482
eISSN: 1471-2482
Links: http://bmcsurg.biomedcentral.com/articles/10.1186/s12893-015-0017-1
http://hdl.handle.net/2381/37442
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: © Gardenbroek et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Description: An erratum to this article can be found at http://​dx.​doi.​org/​10.​1186/​s12893-015-0113-2.
Appears in Collections:Published Articles, College of Medicine, Biological Sciences and Psychology

Files in This Item:
File Description SizeFormat 
art%3A10.1186%2Fs12893-015-0017-1.pdfPublisher version575.44 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.